Abstract
e18231Background: CINV is among the most debilitating and feared consequences of cancer treatment. It is therefore imperative to determine if patients are achieving similar response rates in practice as demonstrated in trials. This study evaluated the real world effectiveness of palonosetron, an NK-1 inhibitor, and dexamethasone in patients receiving HEC for prevention of CINV according to international antiemetic guidelines (ASCO, MASCC, NCCN). Methods: A phase IV prospective, multi-center observational study was conducted in which 107 patients were enrolled and treated in accordance with standard of care. All medications were commercially available and the decision to treat was made by the primary physician prior to and independent of participation in the study. The primary outcome for analysis was complete response (CR) defined as no emetic episodes and no use of rescue medication for CINV. CR was classified as acute- (0-24 hours), delayed-phase ( > 24-120 hours), and overall (0-120 hours). Nausea, vom...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
